This review demonstrates enhanced antitumor activity in solid tumors using innovative CAR-NK and CAR-Mφ therapies, indicating promising future directions.
Key Points
CAR-NK and CAR-Mφ therapies present promising alternatives for treating solid tumors, expanding beyond traditional CAR-T therapies.
Recent innovations like TME-responsive CARs and iPSC-derived platforms boost the effectiveness of these cell therapies.
Preclinical data show improved antitumor activity through mechanisms like MHC-unrestricted cytotoxicity and cross-talk with adaptive immunity.
Challenges persist in persistence and manufacturing, but combinatorial strategies may offer durable, targeted responses in solid tumors.